David Fairlamb, Director of Regulatory Affairs at SolasCure, has been named as a winner at the TOPRA awards.
The awards, organised by The Organisation for Professionals in Regulatory Affairs, are an annual celebration of achievement and best practice in regulatory affairs.
Mr Fairlamb won the Futures category, an Award that acknowledges the role of regulatory scientists in realising the potential of cutting-edge technologies, such as those involving medical devices, advanced therapies and innovative medicines and their delivery systems.
With more than 30 years of global regulatory affairs experience working in industry and consultancy supporting small molecule, biologics, medical devices and combination product development, at SolasCure Mr Fairlamb has shown exceptional leadership in developing and managing a changing regulatory strategy and regulatory operational activities to support the development of novel investigational medicinal product – Aurase Wound Gel.
SolasCure aims to revolutionise wound care treatment by leveraging the power of maggots to create a pioneering new treatment that seeks to allow more effective debridement. Aurase Wound Gel is a hydrogel containing a recombinant enzyme cloned from medical maggots that has the potential to support healthcare professionals treating patients with chronic wounds.
The TOPRA Futures Award focuses on new products and innovative technologies that provide a significant advance in healthcare techniques and improve the delivery and efficacy of existing therapies. Such advances help bring innovative treatments to patients faster by embracing Scientific Advice and combining a flexible and professional approach to certification and licensing with excellence in quality management and benefit-risk assessment. Learn more about the development of Aurase Wound Gel: www.solascure.com/science